These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 36073554)
1. No need of glucocorticoid dose adjustment in patients with adrenal insufficiency before COVID-19 vaccine. Pilli T; Dalmiglio C; Dalmazio G; Sagnella A; Forleo R; Brilli L; Maino F; Ciuoli C; Castagna MG Eur J Endocrinol; 2022 Jul; 187(1):K7-K11. PubMed ID: 36073554 [TBL] [Abstract][Full Text] [Related]
2. Symptoms and steroid dose adjustments following the Covid-19 vaccine in patients with adrenal insufficiency. McLaren DS; Crowe G; Cassidy C; Rasool I; Elsabbagh M; Eyadeh A; Htwe NPPH; Gerrard M; Ward E; Kassim S; Abbas A; Al-Qaissi A; Seejore K; Kyriakakis N; Maguire D; Lynch J; Murray RD Pituitary; 2024 Feb; 27(1):61-69. PubMed ID: 37976013 [TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid use in patients with adrenal insufficiency following administration of the COVID-19 vaccine: a pituitary society statement. Katznelson L; Gadelha M Pituitary; 2021 Apr; 24(2):143-145. PubMed ID: 33564969 [TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336 [TBL] [Abstract][Full Text] [Related]
5. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735 [TBL] [Abstract][Full Text] [Related]
6. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease. Beckley M; Olson AK; Portman MA JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521 [TBL] [Abstract][Full Text] [Related]
7. Safety Monitoring of an Additional Dose of COVID-19 Vaccine - United States, August 12-September 19, 2021. Hause AM; Baggs J; Gee J; Marquez P; Myers TR; Shimabukuro TT; Shay DK MMWR Morb Mortal Wkly Rep; 2021 Oct; 70(39):1379-1384. PubMed ID: 34591835 [TBL] [Abstract][Full Text] [Related]
8. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049 [TBL] [Abstract][Full Text] [Related]
9. Side effects after COVID-19 vaccinations among residents of Poland. Andrzejczak-Grządko S; Czudy Z; Donderska M Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4418-4421. PubMed ID: 34227078 [TBL] [Abstract][Full Text] [Related]
10. Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE-An Observational Study. Ganesan S; Al Ketbi LMB; Al Kaabi N; Al Mansoori M; Al Maskari NN; Al Shamsi MS; Alderei AS; El Eissaee HN; Al Ketbi RM; Al Shamsi NS; Saleh KM; Al Blooshi AF; Cantarutti FM; Warren K; Ahamed F; Zaher W Front Public Health; 2022; 10():876336. PubMed ID: 35602146 [TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol. Patel GB; Chhiba KD; Chen MM; Guo A; Watts MM; Cullen J; Bochner BS; Grammer LC; Greenberger PA; Saltoun CA; Stevens WW; Kuang FL; Peters AT Allergy Asthma Proc; 2021 Nov; 42(6):515-521. PubMed ID: 34871159 [No Abstract] [Full Text] [Related]
12. Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US. Hause AM; Zhang B; Yue X; Marquez P; Myers TR; Parker C; Gee J; Su J; Shimabukuro TT; Shay DK JAMA Netw Open; 2022 Jul; 5(7):e2222241. PubMed ID: 35838667 [TBL] [Abstract][Full Text] [Related]
14. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976 [TBL] [Abstract][Full Text] [Related]
15. Survey of glucocorticoid dose escalation in patients with adrenal insufficiency during the peri-COVID-19 vaccination period. Bando H; Yamamoto M; Takahashi M; Kanie K; Sasaki Y; Oi Y; Tomofuji S; Hozumi K; Nishikage S; Urai S; Yamamoto N; Suzuki M; Shichi H; Iguchi G; Fukuoka H; Ogawa W Endocr J; 2023 Jan; 70(1):89-95. PubMed ID: 36104247 [TBL] [Abstract][Full Text] [Related]
16. Are COVID-19 mRNA vaccine side effects severe enough to cause missed work? Cross-sectional study of health care-associated workers. Cohen DA; Greenberg P; Formanowski B; Parikh PD Medicine (Baltimore); 2022 Feb; 101(7):e28839. PubMed ID: 35363178 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L; Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381 [TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study. Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030 [TBL] [Abstract][Full Text] [Related]
19. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572 [TBL] [Abstract][Full Text] [Related]
20. Adrenal Insufficiency and Glucocorticoid Use During the COVID-19 Pandemic. Almeida MQ; Mendonca BB Clinics (Sao Paulo); 2020; 75():e2022. PubMed ID: 32555949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]